A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000347-14

A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Is to assess whether tesaglitazar given as monotherapy is non-inferior to glibenclamide given as monotherapy during 52 weeks in improving glycaemic control in patients with type 2 diabetes as determined by the absolute change in glycosylated haemoglobin A1c (HbA1c), from baseline to the end of the randomized treatment period.


Critère d'inclusion

  • Men or women who are >18 years of age or older at the enrolment visit (visit 1) diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents